Dyne therapeutics ipo

Author: whab

August undefined, 2024

WebDyne Therapeutics has raised a total of $333M in funding over 4 rounds. Their latest funding was raised on Jan 21, 2024 from a Post-IPO Equity round. Dyne Therapeutics … WebSep 21, 2024 · Dyne is developing a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral ...

DYN Stock Price Dyne Therapeutics Inc. Stock Quote (U.S.: …

WebApr 11, 2024 · Dyne Therapeutics Trading Down 6.0 %. DYN stock opened at $8.82 on Tuesday. The firm has a 50 day moving average of $12.59 and a 200-day moving average of $12.09. The firm has a market ... WebSep 12, 2024 · Dyn Therapeutics (DYN) has filed to raise $175 million from the sale of its common stock in an IPO, according to an amended registration statement.. The company is a preclinical stage developer of ... psychology in the marketplace

Dyne Therapeutics Fills Office-Lab Building in Waltham ... - CoStar

WebSep 17, 2024 · Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price range of $16 and $18, to generate gross ... WebSep 17, 2024 · Dyne Therapeutics Inc, a muscle disease company, has raised about $233 million for its IPO after pricing its over 12.2 million shares at $19 per share. The stock began trading September 17, 2024 on the NASDAQ under the ticker symbol “DYN.” J.P. Morgan, Jefferies, Piper Sandler and Stifel are the lead underwriters. WebSep 17, 2024 · IPOs. Waltham, Massachusetts-based Dyne Therapeutics, Inc. priced its upsized initial public offering of 12.253 million shares at $19 versus the estimated price … hosted services in .net core

Dyne Therapeutics Announces Closing of Initial Public

Dyne Therapeutics Announces Presentations on its DM1 and …

WebAug 26, 2024 · Wednesday’s spinout was prompted by a massive $1.5-plus billion buyout of Tizona by Gilead, announced earlier this month. That agreement gave Gilead 49.9% ownership of ... WebAug 25, 2024 · Dyne Therapeutics, a preclinical biotech developing therapies for muscular diseases, filed on Tuesday with the SEC to raise up to $100 million in an initial public offering. The company is using ... hosted services modelWebSep 17, 2024 · Amid a parade of upsized biotech IPOs this year, Dyne Therapeutics in Waltham made its debut with a $233 million fundraise — more than double what it said it was hoping to bring in when it first ... psychology in the justice system

"WebSep 16, 2024 · WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company focused on advancing … " - Dyne therapeutics ipo

Dyne therapeutics ipo

WebMar 20, 2024 · WALTHAM, Mass., March 20, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. DYN, a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people ... WebApr 4, 2024 · Ticker Symbol: DYN: Exchange: NASDAQ: Fiscal Year: January - December: Reporting Currency: USD: IPO Price: $19.00: CIK Code: 0001379895: CUSIP Number: …

Did you know?

WebApr 11, 2024 · Dyne Therapeutics has a 52-week low of $4.30 and a 52-week high of $15.63. Dyne Therapeutics ( NASDAQ:DYN - Get Rating ) last issued its quarterly earnings data on Thursday, March 2nd. The company reported ($0.74) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.10. WebIPO Pro - "The Ultimate Resource for IPOs" Don't risk buying another IPO without IPO Pro. Get your FREE TRIAL now. Start My 1-Week Trial. Follow Us. IPO ETFs. US IPO ETF; …

WebSep 22, 2024 · Dyne Therapeutics, Inc. rings the Nasdaq Closing Bell remotely from across the country. In celebration of its IPO, Joshua Brumm, President & CEO, rings the Opening Bell alongside the Company’s ... WebSep 17, 2024 · A muscle disease company, Dyne Therapeutics (DYN) has priced its IPO of 12,251,578 common shares at $19.00/share, for expected gross proceeds of …

WebSep 16, 2024 · Dyne Therapeutics, Inc. WALTHAM, Mass., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a muscle disease company … WebMar 14, 2024 · 天眼查为您提供Dyne Therapeutics Inc.的企业信息查询服务，查询Dyne Therapeutics Inc.工商注册信息、公司电话、公司地址、公司邮箱网址、公司经营风险、公司发展状况、公司财务状况、公司股东法人高管、商标、融资、专利、法律诉讼等Dyne Therapeutics Inc.企业信用信息，想了解Dyne Therapeutics Inc.怎么样，就 ...

WebSep 13, 2024 · Summary. Dyne Therapeutics had filed proposed terms for a $175 million U.S. IPO. The firm is advancing treatments for various …

WebSep 17, 2024 · Dyne Therapeutics’ IPO and CureDuchenne’s timely funding is an exemplary model of the CureDuchenne venture philanthropy approach. The CureDuchenne Ventures investment made at a critical time in March 2024 helped Dyne de-risk the science and establish proof-of-concept. They were able to keep working, … psychology in the hunterWebSep 1, 2024 · Dyne Therapeutics (DYN) aims to raise $100 million in an IPO of its common stock, according to an S-1 registration statement. The … hosted sftp ukWebMar 23, 2024 · Dyne Therapeutics sets IPO terms, to offer 10.3 million shares priced at $16 to $18 each. Sep. 10, 2024 at 7:12 a.m. ET by Ciara Linnane. psychology in the news 2018WebPost IPO equity ... Dyne Therapeutics is a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically … hosted services txWeb26 rows · Dyne Therapeutics, Inc. Financial Information: Market Cap: $707.8mil: Revenues: $0 mil (last 12 ... hosted shared desktop citrixWebOct 13, 2024 · Dyne Therapeutics Highlights Preclinical Data and Clinical Development Plans for DMD and DM1 Programs at Inaugural R&D Day. October 13, 2024 07:45 ET Source: Dyne Therapeutics, Inc ... psychology in the modern worldWebAug 26, 2024 · BioNTech signs UK government pact to deliver cancer therapies to 100k patients by 2024. Jan 6, 2024 12:29pm. psychology in the newspaper